Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment
Published on 05/12/2026 at 09:05 am EDT
MT Newswires
Share
Share
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.76 USD | +2.09% |
|
+3.15% | +59.92% |
| Jun. 10 | Alkermes plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10:00 AM | |
| Jun. 09 | Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says | MT |
Employees
2,050
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
43.84USD
Average target price
46.12USD
Spread / Average Target
+5.21%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment
Select your edition
All financial news and data tailored to specific country editions
